Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma-Reference-Cited by-同舟云学术

Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma

Published:2022-04-25 Issue:7 Volume:52 Page:630-640
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatology Research

Author:

Maesaka Kazuki¹,Sakamori Ryotaro¹^ORCID,Yamada Ryoko¹,Doi Akira¹,Tahata Yuki¹,Miyazaki Masanori²,Ohkawa Kazuyoshi³^ORCID,Mita Eiji⁴,Iio Sadaharu⁵,Nozaki Yasutoshi⁶,Yakushijin Takayuki⁷,Imai Yasuharu⁸,Kodama Takahiro¹^ORCID,Hikita Hayato¹^ORCID,Tatsumi Tomohide¹,Takehara Tetsuo¹^ORCID

Affiliation:

1. Department of Gastroenterology and Hepatology Osaka University Graduate School of Medicine Suita Osaka Japan

2. Department of Gastroenterology and Hepatology Osaka Police Hospital Osaka Osaka Japan

3. Department of Hepatobiliary and Pancreatic Oncology Osaka International Cancer Institute Osaka Osaka Japan

4. Department of Gastroenterology and Hepatology National Hospital Organization Osaka National Hospital Osaka Osaka Japan

5. Department of Gastroenterology and Hepatology Hyogo Prefectural Nishinomiya Hospital Nishinomiya Hyogo Japan

6. Department of Gastroenterology and Hepatology Kansai Rosai Hospital Amagasaki Hyogo Japan

7. Department of Gastroenterology and Hepatology Osaka General Medical Center Osaka Osaka Japan

8. Department of Gastroenterology and Hepatology Ikeda Municipal Hospital Ikeda Osaka Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hepr.13771

Reference24 articles.

1. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

2. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

3. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update

4. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

5. Systemic treatment of hepatocellular carcinoma: An EASL position paper

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Heterogeneity in adverse events related to Atezolizumab-Bevacizumab for hepatocellular carcinoma reported in real-life studies;JHEP Reports;2024-08

2. Liver cancer from the perspective of single-cell sequencing: a review combined with bibliometric analysis;Journal of Cancer Research and Clinical Oncology;2024-06-24

3. Is atezolizumab plus bevacizumab as first-line therapy for unresectable hepatocellular carcinoma superior to lenvatinib? a systematic review and meta‑analysis;European Journal of Clinical Pharmacology;2024-06-22

4. Grip strength complements performance status in assessing general condition in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab;Hepatology Research;2024-06-15

5. Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma;PLOS ONE;2024-04-30